What is the ROCE (Return on Capital Employed) of Pharma Mar this year?
The ROCE of Pharma Mar is -0.02 undefined this year.
Pharma Mar ROCE 2024
Pharma Mar ROCE
-0.02
Pharma Mar Dividend yield
1.72 %
Ticker
PHM.MC
ISIN
ES0169501022
WKN
A2P9YT
In 2024, Pharma Mar's return on capital employed (ROCE) was -0.02, a -110.63% increase from the 0.2 ROCE in the previous year.
Pharma Mar Aktienanalyse
What does Pharma Mar do?
Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases. Pharma Mar ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Pharma Mar's Return on Capital Employed (ROCE)
Pharma Mar's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Pharma Mar's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Pharma Mar's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Pharma Mar’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Pharma Mar Stock
How has the ROCE (Return on Capital Employed) of Pharma Mar developed compared to the previous year?
The ROCE of Pharma Mar has increased by -110.63% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Pharma Mar?
A high Return on Capital Employed (ROCE) indicates that Pharma Mar has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Pharma Mar?
A low ROCE (Return on Capital Employed) can indicate that Pharma Mar has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Pharma Mar impact the company?
An increase in the ROCE of Pharma Mar can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Pharma Mar affect the company?
A decrease in ROCE of Pharma Mar can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Pharma Mar?
Some factors that can affect Pharma Mar's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Pharma Mar so important for investors?
The ROCE of Pharma Mar is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Pharma Mar take to improve the ROCE?
To improve the ROCE, Pharma Mar can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Pharma Mar pay?
Over the past 12 months, Pharma Mar paid a dividend of 0.65 EUR . This corresponds to a dividend yield of about 1.72 %. For the coming 12 months, Pharma Mar is expected to pay a dividend of 0.77 EUR.
What is the dividend yield of Pharma Mar?
The current dividend yield of Pharma Mar is 1.72 %.
When does Pharma Mar pay dividends?
Pharma Mar pays a quarterly dividend. This is distributed in the months of May, August, July, July.
How secure is the dividend of Pharma Mar?
Pharma Mar paid dividends every year for the past 9 years.
What is the dividend of Pharma Mar?
For the upcoming 12 months, dividends amounting to 0.77 EUR are expected. This corresponds to a dividend yield of 2.03 %.
In which sector is Pharma Mar located?
Pharma Mar is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharma Mar kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharma Mar from 6/14/2024 amounting to 0.65 EUR, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.
When did Pharma Mar pay the last dividend?
The last dividend was paid out on 6/14/2024.
What was the dividend of Pharma Mar in the year 2023?
In the year 2023, Pharma Mar distributed 0.65 EUR as dividends.
In which currency does Pharma Mar pay out the dividend?
The dividends of Pharma Mar are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharma Mar
Our stock analysis for Pharma Mar Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
